FirsthandHealth
medRxiv PreprintsInternational5 November 2026

Routine Xpert MTB/XDR for Tuberculosis Drug-Resistance Surveillance in Northern Morocco: A Four-Year Programmatic Analysis

This is an official announcement record

Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.

Drug-resistant tuberculosis surveillance requires diagnostic systems that can rapidly identify resistance beyond rifampicin and generate potentially actionable resistance information for routine public-health monitoring. We evaluated programmatic Xpert MTB/XDR use and characterized the molecular resistance profiles generated within a regional tuberculosis diagnostic network in northern Morocco. We retrospectively analyzed 258 Xpert MTB/XDR testing episodes performed from April 2022 to July 2026 and linked available Xpert MTB/RIF Ultra results with target-level molecular outputs. Mycobacterium
Source: medRxiv Preprints
Read the official announcement

Opens www.medrxiv.org

More from medRxiv Preprints

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.